Loading...
Phase II Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal Cell Carcinoma
BACKGROUND: Patients with sarcomatoid renal cell carcinomas (sRCC) have poor outcomes and limited treatment options. Pre-clinical and clinical data suggest susceptibility to cytotoxic agents and vascular endothelial growth factor-targeted therapies. We designed a phase II trial to evaluate the effic...
Na minha lista:
| Udgivet i: | Clin Genitourin Cancer |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5809227/ https://ncbi.nlm.nih.gov/pubmed/28870517 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2017.07.028 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|